We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-7.78%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$147M
AUM Growth
-$20.2M
Cap. Flow
+$2M
Cap. Flow %
1.36%
Top 10 Hldgs %
70.43%
Holding
67
New
5
Increased
11
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$1.19M
2
PRTA icon
Prothena Corp
PRTA
+$621K
3
CYTK icon
Cytokinetics
CYTK
+$442K
4
GOSS icon
Gossamer Bio
GOSS
+$368K
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$239K

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$1.05M
2
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$826K
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$373K
4
HOOK
HOOKIPA Pharma
HOOK
+$183K
5
CCXI
ChemoCentryx, Inc.
CCXI
+$77.9K

Sector Composition

Rank Sector Weight
1 Healthcare 96.08%
2 Energy 2.11%
3 Consumer Staples 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
51
Kiniksa Pharmaceuticals
KNSA
$4.81B
$342K 0.23%
30,000
+10,000
+50% +$130K
AWH
52
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$335K 0.23%
6,874
– –
AKBA icon
53
Akebia Therapeutics
AKBA
$341M
$288K 0.2%
100,000
– –
BCRX icon
54
BioCryst Pharmaceuticals
BCRX
$2.34B
$287K 0.2%
20,000
– –
LSF icon
55
Laird Superfood
LSF
$47.1M
$267K 0.18%
14,000
– –
AVEO
56
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$247K 0.17%
+40,000
New +$239K
ISEE
57
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$244K 0.17%
+15,000
New +$163K
IRTC icon
58
iRhythm Holdings
IRTC
$3.66B
$234K 0.16%
+4,000
New +$212K
SIEN
59
DELISTED
Sientra, Inc.
SIEN
$229K 0.16%
4,000
– –
ARQT icon
60
Arcutis Biotherapeutics
ARQT
$3.49B
$215K 0.15%
9,000
– –
IFRX icon
61
InflaRx
IFRX
$268M
$181K 0.12%
70,000
– –
YTEN
62
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$113K 0.08%
+783
New +$132K
TXMD icon
63
TherapeuticsMD
TXMD
$24M
$74K 0.05%
2,000
– –
CNCE
64
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$65K 0.04%
20,000
– –
HOOK
65
DELISTED
HOOKIPA Pharma
HOOK
– –
-2,000
Closed -$183K
DRNA
66
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-10,000
Closed -$373K
TBIO
67
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-30,000
Closed -$826K
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Birchview Capital held 67 positions worth $147M, down 12% from $167M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Birchview Capital's Q3 2021 filing shows 5 new, 11 increased, 3 reduced and 3 closed positions. Its largest new stake was Gossamer Bio: 40,000 shares worth $503K. The largest sale was Acceleron Pharma, an estimated $1.05M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q3 2021 buy was Gossamer Bio: 40,000 shares worth $503K.
  • Birchview Capital added most to Protagonist Therapeutics in Q3 2021, an estimated $1.19M increase.
  • Birchview Capital's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $1.05M.
  • Birchview Capital fully exited Translate Bio, Inc. Common Stock in Q3 2021, selling an estimated $826K.
  • Birchview Capital's ten largest holdings make up 70% of its $147M portfolio in Q3 2021.
  • Birchview Capital opened 5 new positions and closed 3 in Q3 2021.
  • Birchview Capital's portfolio value fell 12% quarter-over-quarter to $147M.

Based on Birchview Capital's 13F filing for Q3 2021, filed 12 Nov 2021.